{
    "ticker": "ARTL",
    "name": "Artelo Biosciences, Inc.",
    "description": "Artelo Biosciences, Inc. is a biopharmaceutical company focused on developing innovative therapeutics to improve the quality of life for patients suffering from diseases with significant unmet medical needs. Founded in 2015 and headquartered in San Diego, California, Artelo is dedicated to advancing its proprietary portfolio of drug candidates targeting endocannabinoid system receptors. The company is committed to exploring the therapeutic potential of cannabinoids and their applications in various medical conditions, including cancer, chronic pain, and neurological disorders. Artelo is particularly focused on its lead product candidate, ART27.13, which is designed to treat cancer-related anorexia and weight loss. Through rigorous scientific research and clinical studies, Artelo aims to bring new treatment options to market that leverage the therapeutic properties of cannabinoids while ensuring safety and efficacy. Artelo's mission is to harness the power of cannabinoids and transform the landscape of treatment for patients with debilitating conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2015",
    "website": "https://artelobio.com",
    "ceo": "Gregory D. G. D. Shapero",
    "social_media": {
        "twitter": "https://twitter.com/artelobio",
        "linkedin": "https://www.linkedin.com/company/artelo-biosciences/"
    },
    "investor_relations": "https://investors.artelobio.com",
    "key_executives": [
        {
            "name": "Gregory D. G. D. Shapero",
            "position": "CEO"
        },
        {
            "name": "Rafael A. M. S. B. de Lima",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "ART27.13"
            ]
        }
    ],
    "seo": {
        "meta_title": "Artelo Biosciences, Inc. | Innovating Cannabinoid Therapies",
        "meta_description": "Explore Artelo Biosciences, Inc., a biopharmaceutical company dedicated to developing cannabinoid-based therapeutics for serious medical conditions. Learn about our innovative drug candidates and commitment to patient care.",
        "keywords": [
            "Artelo Biosciences",
            "Cannabinoids",
            "Biopharmaceuticals",
            "Cancer Anorexia",
            "Innovative Therapies",
            "ART27.13"
        ]
    },
    "faq": [
        {
            "question": "What is Artelo Biosciences known for?",
            "answer": "Artelo Biosciences is known for developing cannabinoid-based therapeutics for serious medical conditions, particularly cancer-related anorexia."
        },
        {
            "question": "Who is the CEO of Artelo Biosciences?",
            "answer": "Gregory D. G. D. Shapero is the CEO of Artelo Biosciences, Inc."
        },
        {
            "question": "Where is Artelo Biosciences headquartered?",
            "answer": "Artelo Biosciences is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Artelo's lead product candidate?",
            "answer": "Artelo's lead product candidate is ART27.13, designed to treat cancer-related anorexia and weight loss."
        },
        {
            "question": "When was Artelo Biosciences founded?",
            "answer": "Artelo Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "AVGR"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "VRTX",
        "REGN"
    ]
}